Cibus, Inc. (CBUS) Stock Score, Valuation & Financial Research
Cibus, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 12/100.
Quick answer for CBUS
Cibus, Inc. currently has a Wall Street Score of 12/100. The stored market price is $1.49. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is -0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Cibus, Inc. does
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.
CBUS financial snapshot
- Wall Street Score:
- 12/100
- Current price:
- $1.49
- Market capitalization:
- $113.7M
- Revenue:
- $4.3M
- Net income:
- $-98.2M
- Free cash flow:
- $-51.2M
- Cash:
- $20.4M
- Total debt:
- $32.7M
- EPS:
- -1.65
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 37/100
What stands out
- Reported year-over-year revenue growth is +0.2%.
- Free cash flow is $-51.2M, showing cash burn in the current stored period.
- The balance sheet shows $20.4M of cash versus $32.7M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is -0.1 points: CBUS decreased 0.1 points because some fundamentals weakened.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-14.
How to research CBUS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.